Targeting host cell proteases to prevent SARS-CoV-2 invasion
Abstract
Bentham Science - STM publisher of online and print journals, and related print/online book series. Bentham Science answers the information needs of scientists in the fields of pharmaceutical, biomedical, medical, engineering, technology, computer and social sciences.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical efficacy has not yet been definitively proven for indirect antivirals that block viral entry.
“Other indirect antivirals blocking viral cell entry (e.g., by targeting proteases such as TMPRSS2) have been suggested as potential therapies (Kaur et al., 2021), yet definitive proof for clinical efficacy is still lacking.”
From COVID-19 and the human innate immune system (2021) · cites this paper as Kaur et al., 2021
Cited by
Sorted by citations
COVID-19 and the human innate immune system
Schultze, J. L., & Aschenbrenner, A. C. (2021) · Cell · doi:10.1016/j.cell.2021.02.029 · Cited by 714 · see citing works
- Authors
- Kaur, U.
- Corresponding author
- Kaur, Upinder
- ORCID
- Kaur, Upinder
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2021
- Volume
- 22
- Issue
- 2
- Pages
- 192-201
- ISSN
- 1389-4501 (ISSN-L)
- 1873-5592
- OpenAlex
- W4313043204
- Cited by
- 14
- References
- 0
- Citations by year
- 2024: 2 · 2023: 3 · 2022: 5 · 2021: 4
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Drug Targets (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, host cell proteases, viral entry inhibition, protease inhibitors, COVID-19 treatment, host-virus interaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
